Regeneron Pharmaceuticals, Inc. $REGN Position Decreased by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.9% during the third quarter, Holdings Channel reports. The institutional investor owned 129,108 shares of the biopharmaceutical company’s stock after selling 24,392 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Regeneron Pharmaceuticals were worth $97,236,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Orbimed Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth $11,358,000. BlackRock Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $5,682,636,000. Contravisory Investment Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth $6,327,000. Oxbow Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $3,342,000. Finally, Deutsche Bank AG purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $323,249,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 1.7%

NASDAQ REGN opened at $919.96 on Tuesday. The company has a fifty day simple moving average of $806.90 and a two-hundred day simple moving average of $743.66. The stock has a market cap of $94.72 billion, a P/E ratio of 19.49, a P/E/G ratio of 1.38 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 12-month low of $591.52 and a 12-month high of $991.73. The company has a current ratio of 3.35, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The business’s quarterly revenue was up 36.3% compared to the same quarter last year. During the same period in the previous year, the company earned $11.83 earnings per share. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be paid a $0.94 dividend. The ex-dividend date is Friday, November 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.30%.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Huda Zoghbi sold 7,439 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $970.46, for a total transaction of $7,219,251.94. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,652,693.38. The trade was a 81.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Andrew Murphy sold 4,147 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the sale, the insider directly owned 47,833 shares of the company’s stock, valued at approximately $36,960,559.10. This represents a 7.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 27,028 shares of company stock worth $25,025,950 over the last three months. Corporate insiders own 6.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on REGN. Wells Fargo & Company upped their target price on Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the company an “equal weight” rating in a research report on Monday, November 2nd. Canaccord Genuity Group increased their price target on Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. Guggenheim raised their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,100.00 and gave the stock a “buy” rating in a report on Monday, November 2nd. Zacks Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the company an “overweight” rating in a report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $898.97.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions.

The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Founded in 1988, Regeneron is headquartered in Tarrytown, New York.